GB0124523D0 - Pharmaceutical combination - Google Patents

Pharmaceutical combination

Info

Publication number
GB0124523D0
GB0124523D0 GBGB0124523.2A GB0124523A GB0124523D0 GB 0124523 D0 GB0124523 D0 GB 0124523D0 GB 0124523 A GB0124523 A GB 0124523A GB 0124523 D0 GB0124523 D0 GB 0124523D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical combination
pharmaceutical
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0124523.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0124523.2A priority Critical patent/GB0124523D0/en
Publication of GB0124523D0 publication Critical patent/GB0124523D0/en
Priority to AU2002334126A priority patent/AU2002334126B2/en
Priority to JP2003535803A priority patent/JP2005508963A/ja
Priority to CA002463435A priority patent/CA2463435A1/en
Priority to EP02801377A priority patent/EP1434587A1/en
Priority to US10/492,780 priority patent/US20050042171A1/en
Priority to PCT/GB2002/004602 priority patent/WO2003033000A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0124523.2A 2001-10-12 2001-10-12 Pharmaceutical combination Ceased GB0124523D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0124523.2A GB0124523D0 (en) 2001-10-12 2001-10-12 Pharmaceutical combination
AU2002334126A AU2002334126B2 (en) 2001-10-12 2002-10-10 Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
JP2003535803A JP2005508963A (ja) 2001-10-12 2002-10-10 喘息を治療するためのサルメテロールとフルチカゾンプロピオネートを含む医薬の組み合せ
CA002463435A CA2463435A1 (en) 2001-10-12 2002-10-10 Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
EP02801377A EP1434587A1 (en) 2001-10-12 2002-10-10 Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
US10/492,780 US20050042171A1 (en) 2001-10-12 2002-10-10 Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
PCT/GB2002/004602 WO2003033000A1 (en) 2001-10-12 2002-10-10 Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0124523.2A GB0124523D0 (en) 2001-10-12 2001-10-12 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
GB0124523D0 true GB0124523D0 (en) 2001-12-05

Family

ID=9923709

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0124523.2A Ceased GB0124523D0 (en) 2001-10-12 2001-10-12 Pharmaceutical combination

Country Status (7)

Country Link
US (1) US20050042171A1 (enExample)
EP (1) EP1434587A1 (enExample)
JP (1) JP2005508963A (enExample)
AU (1) AU2002334126B2 (enExample)
CA (1) CA2463435A1 (enExample)
GB (1) GB0124523D0 (enExample)
WO (1) WO2003033000A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
CA2417826A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
AR033290A1 (es) 2001-04-30 2003-12-10 Glaxo Group Ltd Derivados antiinflamatorios de androstano
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
CN106075449A (zh) 2005-07-14 2016-11-09 尼奥塞蒂克斯公司 用于局部脂肪组织治疗的持续释放的增强性脂肪分解性制剂
WO2007096782A2 (en) * 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compositions for disorders associated wtth metachromatic cell activation
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
AU2007313077B2 (en) * 2006-10-17 2011-06-02 Neothetics, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
TR201000685A2 (tr) * 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Salmeterol ve flutikazon içeren farmasötik preparatlar.
BR112013012994A2 (pt) 2010-11-24 2016-09-13 Lithera Inc formulações monoterapêuticas de beta-agonista de longa duração, lipofílicas e seletivas e métodos para o tratamento cosmético da adiposidade e saliência de contorno
EP2991626A1 (en) * 2013-04-29 2016-03-09 Sanofi SA Inhalable pharmaceutical compositions and the inhaler devices containing them
PL3054920T3 (pl) * 2013-10-07 2021-07-05 Teva Branded Pharmaceutical Products R&D, Inc. Inhalator suchego proszku
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
GB2235627B (en) * 1989-09-08 1993-09-01 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9924992D0 (en) * 1999-10-21 1999-12-22 Glaxo Group Ltd Pharmaceutical aerosol formulations
GB0021927D0 (en) * 2000-09-07 2000-10-25 Glaxo Group Ltd Use of pharmaceutical combination

Also Published As

Publication number Publication date
AU2002334126B2 (en) 2005-12-15
CA2463435A1 (en) 2003-04-24
WO2003033000A1 (en) 2003-04-24
US20050042171A1 (en) 2005-02-24
EP1434587A1 (en) 2004-07-07
JP2005508963A (ja) 2005-04-07

Similar Documents

Publication Publication Date Title
EP1450824A4 (en) PHARMACEUTICAL COMPOSITION
GB0104534D0 (en) Pharmaceutical combination
PL366510A1 (en) Pharmaceutical combinations
HUP0303163A3 (en) Tramadol-based pharmaceutical composition
GB0117057D0 (en) Pharmaceutical composition
GB0101227D0 (en) Pharmaceutical compounds
GB0129117D0 (en) Pharmaceutical composition
GB0101225D0 (en) Pharmaceutical compounds
GB0116107D0 (en) Pharmaceutical composition
GB0127805D0 (en) Pharmaceutical composition
PL370037A1 (en) Pharmaceutical composition
GB0129270D0 (en) Pharmaceutical combination
GB0129397D0 (en) Pharmaceutical combination
GB0129872D0 (en) Novel pharmaceutical
GB0129395D0 (en) Pharmaceutical combination
IL157411A0 (en) Pharmaceutical composition
GB0128138D0 (en) Pharmaceutical use
GB0129876D0 (en) Novel pharmaceutical
GB0130510D0 (en) Novel pharmaceutical
GB0130511D0 (en) Novel pharmaceutical
GB0130509D0 (en) Novel pharmaceutical
GB0129871D0 (en) Novel pharmaceutical
GB0129275D0 (en) Pharmaceutical combination
GB0129396D0 (en) Pharmaceutical combination
HU0103049D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)